Janssen Research and Development ▲ Sign in to save

• ▲ JESSICA T. VERMEULEN

  Johnson & Johnson (Netherlands) Medicine
  10.5k

  citations

  42

  h-index

  51

  Aachen papers
• ▲ Emilie M.J. van Brummelen

  Johnson & Johnson (Netherlands) Medicine
  4.84k

  citations

  22

  h-index

  26

  Aachen papers
• ▲ Carla de Boer

  Medicine
  3.02k

  citations

  19

  h-index

  11

  Aachen papers
• ▲ Carla J. de Boer

  Medicine
  3k

  citations

  18

  h-index

  6

  Aachen papers
• ▲ NamPhuong Tran

  Johnson & Johnson (United States) Medicine
  2.21k

  citations

  22

  h-index

  1

  Aachen papers
• ▲ Tobias Kampfenkel

  Johnson & Johnson (Germany) · Janssen (Germany) Medicine
  2.16k

  citations

  17

  h-index

  19

  Aachen papers
• ▲ Remy B. Verheijen

  Johnson & Johnson (Netherlands) Medicine
  2.06k

  citations

  20

  h-index

  4

  Aachen papers
• ▲ Brenda J. Tromp

  Janssen (Netherlands) · Janssen Research & Development (United States) Medicine
  1.74k

  citations

  9

  h-index

  18

  Aachen papers
• ▲ Martinus A.H. Capelle

  Johnson & Johnson (Netherlands) Biochemistry, Genetics and Molecular Biology
  689

  citations

  15

  h-index

  2

  Aachen papers
• ▲ Nina Hertoghs

  Janssen (Netherlands) · Johnson & Johnson (Netherlands) Medicine
  592

  citations

  11

  h-index

  4

  Aachen papers
• ▲ Bart van Hartingsveldt

  Janssen (Netherlands) · Johnson & Johnson (Netherlands) Medicine
  294

  citations

  6

  h-index

  6

  Aachen papers
• ▲ Max Beugeling

  Janssen (Netherlands) Pharmacology, Toxicology and Pharmaceutics
  162

  citations

  6

  h-index

  1

  Aachen papers
• ▲ Hein Ludlage

  Janssen (Netherlands) Medicine
  143

  citations

  2

  h-index

  1

  Aachen papers
• ▲ A.J.P. van Heugten

  Janssen (Netherlands) Chemistry
  87

  citations

  6

  h-index

  1

  Aachen papers
• ▲ J. van de Logt

  Janssen (Netherlands) Medicine
  36

  citations

  2

  h-index

  2

  Aachen papers

15 results

• Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

  2020 Blood article Medicine Multiple Myeloma Research and Treatments Open access

  703

  citations
• Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

  2021 New England Journal of Medicine article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes Open access cited by 1 patent

  701

  citations
• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

  2023 New England Journal of Medicine article Medicine Multiple Myeloma Research and Treatments Open access cited by 1 patent

  588

  citations
• Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  376

  citations
• Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access cited by 13 patents

  345

  citations
• Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  182

  citations
• Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

  2024 Journal of Clinical Oncology article Medicine Lung Cancer Treatments and Mutations Open access cited by 3 patents

  132

  citations
• Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

  2024 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  130

  citations
• Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

  2025 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access

  113

  citations
• Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

  2021 Haematologica article Medicine Multiple Myeloma Research and Treatments Open access

  54

  citations
• Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

  2020 Blood article Medicine Multiple Myeloma Research and Treatments

  51

  citations
• Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

  2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 1 patent

  36

  citations
• Bedaquiline for multidrug-resistant TB in paediatric patients

  2021 The International Journal of Tuberculosis and Lung Disease article Medicine Tuberculosis Research and Epidemiology Open access

  27

  citations
• Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

  2022 Haematologica article Medicine Multiple Myeloma Research and Treatments Open access

  26

  citations
• Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

  2021 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments

  24

  citations
• Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

  2022 British Journal of Haematology article Medicine Multiple Myeloma Research and Treatments Open access

  24

  citations
• Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

  2020 Blood article Medicine Multiple Myeloma Research and Treatments

  24

  citations
• Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

  2021 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments

  21

  citations
• Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study

  2022 Journal of Nuclear Medicine article Medicine Multiple Myeloma Research and Treatments Open access

  19

  citations
• Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

  2024 Journal of Clinical Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations Open access

  19

  citations